The German private company Stada is, in our view, a resourceful partner with a strategic interest in expanding the speciality pharma market for Callidita's late-stage orphan candidate Nefecon. The deal structure is favourable and supports this view. Stada is likely to work hard to make the most out of EUR 97.5m in milestones and sales royalties between 20-30%.